Novel Coronavirus Pneumonia (COVID-19)
Conditions
Interventions
experimental group:Rabeprazole plus chloroquine
control group :Lopinavir + rabeprazole
Sponsors
Infection prevention and treatment center of The Fifth Affiliated Hospital of Sun Yat-Sen University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 75 years old; 2. mild or normal patients; 3. not using chloroquine phosphate, lopinavir other than other antiviral drugs; 4. under the gastroscope, there was mucosal damage and pathological biopsy of 2019-ncov nucleic acid positive; 5. confirmed cases meeting all the following criteria (the 5th edition of the medical guidelines): (1) epidemiological history; (2) Clinical manifestations (in accordance with any 2 of the following): fever; In the early stage of the disease, the total number of white blood cells was normal or decreased, or the lymphocyte count was decreased. In the early stage of chest imaging, multiple small plaques and stromal changes were observed, especially in the lung. Then, it developed into multiple ground-glass shadows and infiltrating shadows in both lungs. In severe cases, lung consolidation may occur, and pleural effusion is rare; (3) Confirmed: the suspected case has one of the following etiological evidence: respiratory or blood specimens were tested positive for novel coronavirus nucleic acid by real-time fluorescent rt-pcr; Respiratory or blood specimen virus gene sequencing, and known novel coronavirus highly homologous.
Exclusion criteria
Exclusion criteria: 1. in pregnancy, breast-feeding female patients; 2. to determine the history of chloroquine phosphate, rabeprazole drug allergy patients; Patients suffering from diseases of the blood system; 3. patients suffering from chronic liver and kidney diseases and reaching the terminal stage; 4. Serious heart, lung dysfunction and mental illness; 5. Patients with known retinal diseases, hearing loss or hearing loss; 6. Patients who have to take digitalis drugs for existing underlying diseases; 7. Merger of other digestive tract diseases; 8. Combine ribavirin; 9. Involved in other processing clinical drug trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2019-ncov nucleic acid yin rate;Blood 2019-ncov nucleic acid positive;Positive 2019-ncov nucleic acid in feces;Nasopharyngeal swab positive for 2019-ncov nucleic acid; | — |
Countries
China
Contacts
Public ContactXiao Fei
The Fifth Affiliated Hospital of Sun Yat-Sen University
Outcome results
None listed